American Society of Clinical Oncology (ASCO) shared on LinkedIn:
“ASCO Updates Living Guidelines for Stage IV NSCLC With Driver Alterations: Clinical practice guidelines now support entrectinib, larotrectinib, or repotrectinib for patients with NTRK fusion-positive locally advanced or metastatic solid tumors.
Key Takeaways:
- Efficacy: Achieved a 59% confirmed objective response rate (cORR) in TKI-naïve patients, with a 16% complete response rate.
- CNS Penetration: Demonstrated robust intracranial activity, including complete intracranial responses in baseline measurable lesions.
- Safety Considerations: Grade 3+ TRAEs occurred in 34% of patients. Repotrectinib’s safety profile is characterized primarily by dizziness and dysgeusia, offering a distinct profile compared to entrectinib (weight gain/anemia) and larotrectinib (transaminitis/cytopenias).
Selection among these targeted therapies should balance CNS disease presence, drug availability, and individualized toxicity profiles.”
Other articles about NSCLC on OncoDaily.